Literature DB >> 22469572

Upper tract urothelial carcinoma: current treatment and outcomes.

Benjamin T Ristau1, Jeffrey J Tomaszewski, Michael C Ost.   

Abstract

The reference standard treatment of upper tract urothelial carcinoma is open radical nephroureterectomy. Many centers have advocated less-invasive treatment modalities. We reviewed contemporary treatments of upper tract urothelial carcinoma and their outcomes. A MEDLINE search was conducted for all relevant published data during the past 15 years. Endoscopic management is feasible for low-grade disease with strict surveillance protocols. Radical nephroureterectomy remains the reference standard for upper tract urothelial carcinoma. The intermediate-term oncologic outcomes are similar between the laparoscopic and open approaches. Controversies still exist regarding the optimal management of the distal ureter, the utility of topical therapy, and the role of lymphadenectomy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22469572     DOI: 10.1016/j.urology.2011.12.024

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  13 in total

1.  Comparison of post-operative intravesical recurrence and oncological outcomes after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma.

Authors:  Lujia Zou; Limin Zhang; Hu Zhang; Haowen Jiang; Qiang Ding
Journal:  World J Urol       Date:  2014-04       Impact factor: 4.226

Review 2.  Upper tract urothelial carcinoma: Paradigm shift towards nephron sparing management.

Authors:  Julia V Fiuk; Brad F Schwartz
Journal:  World J Nephrol       Date:  2016-03-06

3.  Treatment Effects of WST11 Vascular Targeted Photodynamic Therapy for Urothelial Cell Carcinoma in Swine.

Authors:  Katie S Murray; Ashley G Winter; Renato Beluco Corradi; Stephen LaRosa; Sylvia Jebiwott; Alexander Somma; Haruyuki Takaki; Govindarajan Srimathveeravalli; Michelle Lepherd; Sebastien Monette; Kwanghee Kim; Avigdor Scherz; Jonathan A Coleman
Journal:  J Urol       Date:  2016-02-06       Impact factor: 7.450

4.  Laparoscopic radical nephroureterectomy is associated with worse survival outcomes than open radical nephroureterectomy in patients with locally advanced upper tract urothelial carcinoma.

Authors:  Hyung Suk Kim; Ja Hyeon Ku; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim
Journal:  World J Urol       Date:  2015-10-23       Impact factor: 4.226

5.  Conservative nephron-sparing treatment of upper-tract tumors.

Authors:  Paul Smith; Juliette Mandel; Jay D Raman
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

6.  Neurotensin branched peptide as a tumor-targeting agent for human bladder cancer.

Authors:  Jlenia Brunetti; Chiara Falciani; Barbara Lelli; Andrea Minervini; Niccolò Ravenni; Lorenzo Depau; Giampaolo Siena; Eleonora Tenori; Stefano Menichetti; Alessandro Pini; Marco Carini; Luisa Bracci
Journal:  Biomed Res Int       Date:  2015-04-23       Impact factor: 3.411

7.  Endoscopic management of upper urinary tract urothelial carcinoma.

Authors:  Bong Hee Park; Seong Soo Jeon
Journal:  Korean J Urol       Date:  2013-07-15

8.  Diagnostic Ureterorenoscopy Is Associated with Increased Intravesical Recurrence following Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma.

Authors:  Hyun Hwan Sung; Hwang Gyun Jeon; Deok Hyun Han; Byong Chang Jeong; Seong Il Seo; Hyun Moo Lee; Han-Yong Choi; Seong Soo Jeon
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

Review 9.  Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer.

Authors:  Azharuddin Mohammed; Zubair Arastu
Journal:  BMC Urol       Date:  2017-12-06       Impact factor: 2.264

10.  Impact of gender on tumor stage and survival of upper urinary tract urothelial cancer : A population-based study.

Authors:  Badereddin Mohamad Al-Ali; Stephan Madersbacher; Nadine Zielonke; Ingrid Schauer; Thomas Waldhoer; Gerald Haidinger
Journal:  Wien Klin Wochenschr       Date:  2016-09-26       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.